<unk>  is a nucleoside analogue that is FDA approved for the treatment of chronic hepatitis C (CHC) virus infection in combination with peginterferon alfa-2a in adults with compensated liver disease not previously treated with interferon alpha, and in CHC patients coinfected with HIV-1. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include injection site reaction, pruritus, weight decrease, diarrhea, gastrointestinal symptoms, loss of appetite, nausea, vomiting, neutropenia, asthenia, dizziness, excluding vertigo, headache, insomnia, fatigue and influenza-like illness.
Ribavirin
Telaprevir
Saquinavir
Abacavir
Lamivudine
Adefovir
Telbivudine
Fosamprenavir